Emile Klada
Pulmonary Disease · Sylvania, OHNPI 1316243355
Payments from drug & device makers
Across 338 payments — averaging $18.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$848
- GSK$645
- Boehringer Ingelheim$615
- United Therapeutics Corporation$465
- Baxter Healthcare$406
- Grifols USA, LLC$399
- plus $3K from 32 others
What the payments were for
- Speaking & faculty fees$1002%
- Food & beverage$5,81293%
- Education$3255%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 48 | $848 |
| GSK | 52 | $645 |
| Boehringer Ingelheim | 34 | $615 |
| United Therapeutics Corporation | 21 | $465 |
| Baxter Healthcare | 13 | $406 |
| Grifols USA, LLC | 22 | $399 |
| Regeneron Healthcare Solutions, Inc. | 12 | $391 |
| Insmed, Inc. | 16 | $280 |
| Merck | 15 | $255 |
| Sanofi | 9 | $176 |
| Actelion Pharmaceuticals US, Inc. | 7 | $164 |
| Mylan Specialty L.p. | 9 | $139 |
| Johnson & Johnson | 8 | $134 |
| Astellas Pharma US Inc | 5 | $131 |
| Mallinckrodt Hospital Products Inc. | 5 | $122 |
| Advanced Respiratory, Inc | 6 | $110 |
| Gilead | 6 | $105 |
| La Jolla Pharmaceutical Company | 6 | $94 |
| Phadia US Inc. | 4 | $70 |
| Amgen | 4 | $69 |
| Electromed, Inc. | 5 | $64 |
| Philips North America LLC | 3 | $64 |
| CSL Behring | 1 | $57 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $56 |
| Bayer | 3 | $51 |
| Jazz Pharmaceuticals Inc. | 3 | $50 |
| Sunovion Pharmaceuticals Inc. | 5 | $45 |
| Harmony Biosciences LLC | 1 | $30 |
| Novartis | 2 | $29 |
| Inogen, Inc. | 2 | $28 |
| Viatris Specialty LLC | 1 | $25 |
| Resmed Corp | 1 | $21 |
| Chiesi USA, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $18 |
| Inspire Medical Systems, Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $14 |
| Circassia Inc. | 1 | $14 |
| Pulmonx Corporation | 1 | $14 |
How this compares
$6,237 in reported general payments places this provider in the 65th percentile of 571 pulmonary disease providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 27 | $387,697 |
| Orenitram ErTreprostinil Diolamine | 12 | $305,461 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 347 | $270,453 |
| Ambrisentan | 11 | $66,540 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 63 | $47,670 |
| Breo ElliptaFluticasone/Vilanterol | 107 | $42,876 |
| Tadalafil | 18 | $39,820 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 56 | $35,206 |
| Incruse ElliptaUmeclidinium Bromide | 32 | $11,701 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 31 | $11,377 |
| SymbicortBudesonide/Formoterol Fumarate | 22 | $6,599 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 190 | $6,504 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 13 | $5,540 |
| Roflumilast | 21 | $4,602 |
| Ventolin HfaAlbuterol Sulfate | 14 | $665 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Stiolto Respimat | $615 | $393,23840 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $645 | $372,700549 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $848 | $41,80578 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 571 pulmonary disease providers in Ohio.
Other pulmonary disease in Sylvania
- Bruce CorserCincinnati$8.2M
- Edward CordascoColumbus$8M
- Kristin HighlandCleveland$3.2M
- Brian ZenoColumbus$2.9M
- Jean ElwingCincinnati$2.4M
- Roy St JohnColumbus$1.9M
- Nishant GuptaCincinnati$1.5M
- Robert BaughmanCincinnati$1.1M
- Francis McCormackCincinnati$1.1M
- Leslie TolleCleveland$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.